Post-marketing Study Mandates Could Drive R&D Strategy – DIA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies should include post-market “burden” in calculus of drug development decisions, Tufts analyst suggests.
You may also be interested in...
REMS Not Anticipated For Every NME – FDA Official
CDER's Sandra Kweder aims to allay industry worries at Drug Industry Association meeting in Boston.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.